Sens. Susan Collins (L) and Shelley Moore Capito (J. Scott Applewhite/AP Images)
March 3, 2022 07:09 AM ESTUpdated 07:40 AM
FDA+

Two Re­pub­li­can sen­a­tors call on CMS to not re­strict cov­er­age to amy­loid-tar­get­ed Alzheimer's drugs

Zachary Brennan

Senior Editor

Re­pub­li­can Sen­a­tors Su­san Collins of Maine and Shel­ley Moore Capi­to of West Vir­ginia re­cent­ly sent a let­ter to CMS, urg­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times